HLS Therapeutics (HLS Therapeutics) Debt-to-Equity : 0.90 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is HLS Therapeutics Debt-to-Equity?

HLS Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.16 Mil. HLS Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $82.47 Mil. HLS Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $97.70 Mil. HLS Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.90.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for HLS Therapeutics's Debt-to-Equity or its related term are showing as below:

HLTRF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.52 Med: 0.63 Max: 0.9
Current: 0.9

During the past 13 years, the highest Debt-to-Equity Ratio of HLS Therapeutics was 0.90. The lowest was 0.52. And the median was 0.63.

HLTRF's Debt-to-Equity is ranked worse than
83.53% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs HLTRF: 0.90

HLS Therapeutics Debt-to-Equity Historical Data

The historical data trend for HLS Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Debt-to-Equity Chart

HLS Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.52

0.63

0.61

0.78

0.90

HLS Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.78	0.80	0.84	0.89	0.90

Competitive Comparison of HLS Therapeutics's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HLS Therapeutics's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Debt-to-Equity falls into.

HLS Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

HLS Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.156	+	82.465)	/	97.697
	=	0.90

HLS Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.156	+	82.465)	/	97.697
	=	0.90

HLS Therapeutics (OTCPK:HLTRF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

HLS Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

HLS Therapeutics (HLS Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (OTCPK:HLTRF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

HLS:Canada

Address

10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2

Website

https://www.hlstherapeutics.com

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.

HLS Therapeutics (HLS Therapeutics) Headlines

From GuruFocus

Automodular Corp. (TSX:AM) - Strong Buy

By Elliot Luchansky, CFA Elliot Luchansky, CFA • 03-21-2013